文献速递前列腺癌

低剂量率近距离放疗治疗高复发风险局限性前列腺癌

Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
PubMed 文献 · BJU Int · 2018-05-08

该研究基于单中心前瞻性队列,分析125I低剂量率前列腺近距离放疗(LDR-PB)单用或联合雄激素剥夺治疗(ADT)和/或外照射放疗(EBRT)在高危局限性前列腺癌中的临床结局。按NICE和NCCN标准分别识别267例和202例高危患者,9年无复发生存率分别为89%和87%(P=0.637),总生存率分别为93%和94%(P=0.481)。结论认为LDR-PB对高危局限性前列腺癌有效,但非随机设计无法明确哪些患者需联合ADT和/或EBRT。

要点

  • NICE与NCCN标准识别的267例和202例高危患者9年RFS分别为89%和87%(P=0.637)。
  • LDR-PB单药与联合治疗的生存估计及治疗相关毒性相似。
  • 非随机设计无法确定需加用ADT和/或EBRT的患者,NICE标准或适合指导治疗选择。

核心结论

  • LDR-PB能有效控制高复发风险局限性前列腺癌。
  • 因研究非随机,无法定义需加用ADT和/或EBRT的患者。
  • NICE标准似乎适合用于界定可从LDR-PB单药或联合治疗中获益的患者。

研究设计与样本

  • 单中心前瞻性队列分析,患者接受LDR-PB单用或联合治疗。
  • 按NICE标准识别267例高危患者,按NCCN标准识别202例高危患者。

主要发现

  • NICE定义的患者治疗前PSA显著更低、Gleason评分<7者更多、接受LDR-PB单药比例更高。
  • 植入后9年RFS在NICE组为89%、NCCN组为87%(log-rank P=0.637)。
  • 9年OS在NICE组为93%、NCCN组为94%(log-rank P=0.481)。
  • LDR-PB单药与联合治疗的生存估计及治疗相关毒性相似。
  • Cox比例风险回归证实不同治疗类型的RFS相似。

关键数值与推荐

  • 高危患者分别按NICE标准(267例)和NCCN标准(202例)界定。

临床怎么用

  • LDR-PB可作为高复发风险局限性前列腺癌的治疗选择。
  • 选择单药或联合ADT和/或EBRT需与患者讨论,并考虑合并症及多重高危因素。
  • NICE标准或有助于指导LDR-PB单药或联合治疗的决策。

局限性

  • 研究非随机,无法明确需加用ADT和/或EBRT的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report clinical outcomes of 125 I low-dose-rate prostate brachytherapy (LDR-PB) as monotherapy or combined with androgen-deprivation therapy (ADT) and/or external beam radiotherapy (EBRT) in high-risk localised prostate cancer. PATIENTS AND METHODS: Analysis of clinical outcomes from a prospective cohort of patients treated with LDR-PB alone or combined treatment in a single institution. Men with a high risk of disease relapse were identified by the National Institute for Health and Care Excellence (NICE) criteria or by the National Comprehensive Cancer Network (NCCN) criteria. Relapse-free survival (RFS), overall survival (OS), prostate cancer-specific survival (PCSS), and metastases-free survival (MFS), were analysed together with patient-reported symptom scores and physician-reported adverse events. RESULTS: The NICE and NCCN criteria identified 267 and 202 high-risk patients, respectively. NICE-defined patients had significantly lower pre-treatment PSA levels, Gleason scores <7, and a greater proportion of patients who received LDR-PB monotherapy. At 9 years after implantation RFS was 89% and 87% in the NICE and NCCN groups, respectively (log-rank P = 0.637), and OS 93% and 94%, respectively (log-rank P = 0.481). All of the survival estimates were similar between LDR-PB monotherapy and combined therapies. Cox proportional hazards regression confirmed RFS was similar between the treatment types. Treatment-related toxicity was also similar between the treatment methods. CONCLUSION: LDR-PB is effective at controlling localised prostate cancer in patients with a high risk of disease relapse. As the present study was not randomised, it is not possible to define those patients who need the addition of ADT and/or EBRT. However, the NICE criteria appear suitable to define treatment options where patients could benefit from LDR-PB as monotherapy or combined treatment. This choice should be discussed with the patient taking into account comorbidities and presence of multiple high-risk factors.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Laing R, Uribe J, Uribe-Lewis S, et al. Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse. BJU Int. 2018. PMID: 29607601. doi:10.1111/bju.14223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。